- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00349752
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)
10 juillet 2018 mis à jour par: UCB Pharma
A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.
The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease.
Subjects had to be in remission (CDAI<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Aperçu de l'étude
Statut
Résilié
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
174
Phase
- Phase 3
Accès étendu
Disponible en dehors de l'essai clinique.
Voir enregistrement d'accès étendu.
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Frankfurt, Allemagne
-
Heidleberg, Allemagne
-
Jena, Allemagne
-
Magdeburg, Allemagne
-
Ulm, Allemagne
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Abbotsford, British Columbia, Canada
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis
-
Montgomery, Alabama, États-Unis
-
-
Arizona
-
Tucson, Arizona, États-Unis
-
-
California
-
La Jolla, California, États-Unis
-
Oceanside, California, États-Unis
-
Orange, California, États-Unis
-
Palo Alto, California, États-Unis
-
Roseville, California, États-Unis
-
-
Colorado
-
Golden, Colorado, États-Unis
-
-
Florida
-
Clearwater, Florida, États-Unis
-
Gainesville, Florida, États-Unis
-
Hialeah, Florida, États-Unis
-
Jacksonville, Florida, États-Unis
-
North Miami Beach, Florida, États-Unis
-
Sarasota, Florida, États-Unis
-
Winter Park, Florida, États-Unis
-
-
Georgia
-
Marietta, Georgia, États-Unis
-
Savannah, Georgia, États-Unis
-
-
Illinois
-
Chicago, Illinois, États-Unis
-
-
Indiana
-
Bloomington, Indiana, États-Unis
-
-
Kansas
-
Topeka, Kansas, États-Unis
-
-
Kentucky
-
Bowling Green, Kentucky, États-Unis
-
Louisville, Kentucky, États-Unis
-
-
Louisiana
-
Metairie, Louisiana, États-Unis
-
-
Maryland
-
Annapolis, Maryland, États-Unis
-
-
Massachusetts
-
Newton, Massachusetts, États-Unis
-
-
Michigan
-
Chesterfield, Michigan, États-Unis
-
Dearborn, Michigan, États-Unis
-
Troy, Michigan, États-Unis
-
-
Minnesota
-
Rochester, Minnesota, États-Unis
-
-
Mississippi
-
Ocean Springs, Mississippi, États-Unis
-
-
Missouri
-
Kansas City, Missouri, États-Unis
-
Mexico, Missouri, États-Unis
-
-
New York
-
New York, New York, États-Unis
-
Syracuse, New York, États-Unis
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis
-
Charlotte, North Carolina, États-Unis
-
Raleigh, North Carolina, États-Unis
-
-
Ohio
-
Cincinnati, Ohio, États-Unis
-
Cleveland, Ohio, États-Unis
-
Dayton, Ohio, États-Unis
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis
-
-
South Carolina
-
Columbia, South Carolina, États-Unis
-
-
Tennessee
-
Germantown, Tennessee, États-Unis
-
-
Texas
-
Austin, Texas, États-Unis
-
Irving, Texas, États-Unis
-
-
Utah
-
Salt Lake City, Utah, États-Unis
-
-
Vermont
-
Burlington, Vermont, États-Unis
-
-
Virginia
-
Chesapeake, Virginia, États-Unis
-
Richmond, Virginia, États-Unis
-
-
Washington
-
Seattle, Washington, États-Unis
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis
-
Milwaukee, Wisconsin, États-Unis
-
Monroe, Wisconsin, États-Unis
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Men and women
- Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)
Exclusion Criteria:
- Active or draining fistula present at screening
- Lactating and/or pregnant female subjects
- A history of any health condition that could potentially interfere with the disease and/or the treatment
- A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product
- Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study
- History of drug or alcohol abuse in the prior year
- Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
|
|
Expérimental: Certolizumab pegol 400 mg
|
Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38
Délai: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
|
Week 38
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Subjects With Continuous Remission Off Steroids at Week 38
Délai: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A subject with continuous remission off steroids at Week 38 is a subject in remission (CDAI =< 150) from the visit when he stops taking steroids to Week 38 and is off corticosteroids until Week 38.
|
Week 38
|
|
Cumulative Percentage of Subjects With Relapse/Treatment Failure at Week 38
Délai: Week 38
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
Week 38
|
|
Time to Relapse/Treatment Failure During the 38-week Double-blind Treatment Period
Délai: During the 38-week double-blind treatment period
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
During the 38-week double-blind treatment period
|
|
Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Délai: Over the 38-week double-blind treatment period
|
The median weekly dose of corticosteroids is calculated for each subject, and these per-subject median values are further summarized by treatment group.
The mean of the per-subject median doses in each treatment group is presented here.
|
Over the 38-week double-blind treatment period
|
|
Per-subject Cumulative Dose of Corticosteroids Over the 48-week Study Period
Délai: Over the 48-week study period
|
The cumulative dose of corticosteroids over the 48-week study period is calculated for each subject individually.
The mean of these values for each treatment group is presented here.
|
Over the 48-week study period
|
|
Change From the 6-week run-in Period in Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Délai: 6-week run-in period, 38-week double-blind treatment period
|
The run in period lasted a minimum of 1 week and a maximum of 6 weeks.
During this period subjects were treated with any dose or type of systemic corticosteroids the Investigator felt was appropriate.
To be eligible for study randomization, subjects must have been in remission (CDAI ≤150 points) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Subjects who did not meet these criteria were not randomized and were withdrawn from the study.
|
6-week run-in period, 38-week double-blind treatment period
|
|
Crohn's Disease Activity Index (CDAI) Score at Week 38
Délai: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 38
|
|
Change From Baseline in CDAI Score at Week 38
Délai: Week 0, Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 0, Week 38
|
|
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Délai: Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher score indicates a better quality of life.
IBDQ remission is defined as a subject having an IBDQ total score >= 170 points.
|
Week 38
|
|
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Délai: Week 0, Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher scores indicates a better quality of life.
IBDQ response is defined as an increase from baseline in the IBDQ total score >= 16 points.
|
Week 0, Week 38
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Liens utiles
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 novembre 2006
Achèvement primaire (Réel)
1 juillet 2009
Achèvement de l'étude (Réel)
1 juillet 2009
Dates d'inscription aux études
Première soumission
30 juin 2006
Première soumission répondant aux critères de contrôle qualité
6 juillet 2006
Première publication (Estimation)
10 juillet 2006
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
9 août 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
10 juillet 2018
Dernière vérification
1 octobre 2010
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- C87059
- 2006-003870-88 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .